TICKERNERD
Menu
ALNYALNYHealthcare · Biotechnology

ALNY Stock Forecast: Alnylam Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$229
+0.67% on the day

The 27 Wall Street analysts covering Alnylam Pharmaceuticals, Inc. hold a median 12-month price target of $354 — +54.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 54 of 100 as at 15 Aug 2026 — in the upper half.

Market cap
$30.6B
Ticker Nerd rank
54 / 100
Median analyst target
$354
Analysts covering
27
Total return, dividends reinvested
1W
+4.3%
1M
−18.7%
YTD
−42.5%
1Y
−48.4%
From 52W high
−53.5%
From 52W low
+11.3%
$205
$491
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ALNY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Alnylam Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
54 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
97
Growth
96
Quality
94
Volatility
89
Revisions
38
Momentum
30
Accruals
28
Issuance
27
Size
8

Value (97): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (27): The company has been issuing shares or taking on financing, diluting existing holders.

Size (8): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ALNY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALNY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$200$300$400$500$600Oct 25Jan 26Apr 26Jul 26ALNYHigh $536Median $354Low $230

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says27 analysts
21 Buy6 Hold0 Sell
Low $230Median $354High $536

The green dot is the last close — the median target sits +54.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 13 moved it down.

DateFirmActionRatingTarget
4 Aug 2026HC Wainwright & Co.MaintainsBuy$485 → $455
4 Aug 2026Truist SecuritiesMaintainsBuy$410 → $315
3 Aug 2026BarclaysMaintainsOverweight$527 → $450
3 Aug 2026CitigroupMaintainsBuy$380 → $340
3 Aug 2026Raymond JamesUpgradeStrong Buy$420
31 July 2026Chardan CapitalMaintainsBuy$425
31 July 2026JP MorganMaintainsOverweight$400 → $375
31 July 2026Morgan StanleyMaintainsEqual-Weight$400 → $300
31 July 2026OppenheimerMaintainsOutperform$500 → $350
31 July 2026RBC CapitalMaintainsOutperform$445 → $350
31 July 2026StifelMaintainsBuy$444 → $318
31 July 2026Wells FargoMaintainsEqual-Weight$377 → $316
30 July 2026NeedhamMaintainsBuy$510 → $357
22 July 2026JP MorganMaintainsOverweight$420 → $400
22 July 2026JP MorganMaintainsOverweight—
14 July 2026B of A SecuritiesMaintainsBuy$460 → $410
14 July 2026B of A SecuritiesMaintainsBuy—
13 July 2026HC Wainwright & Co.MaintainsBuy—
13 July 2026HC Wainwright & Co.MaintainsBuy$470 → $485
13 July 2026Truist SecuritiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALNY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ALNY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−4.3%
Analysts raising
2
Analysts cutting
3
Fundamentals

Alnylam Pharmaceuticals, Inc. (ALNY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
39.8×

Cheaper than 20% of US stocks

Price / sales
6.4×

Cheaper than 21% of US stocks

Price / book
22.6×

Cheaper than 5% of US stocks

EV / EBITDA
28.7×

Cheaper than 10% of US stocks

Growth & margins
Revenue growth (YoY)
66.9%

Higher than 90% of US stocks

Earnings growth (YoY)
66.9%

Higher than 80% of US stocks

Gross margin
76.9%

Higher than 89% of US stocks

Operating margin
17.9%

Higher than 76% of US stocks

Net margin
16.1%

Higher than 79% of US stocks

Returns & dividend
Return on equity
96.6%

Higher than 96% of US stocks

Return on assets
12.3%

Higher than 95% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ALNY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ALNYAlnylam Pharmaceuticals, Inc.$30.6B
54
RPRXRoyalty Pharma plc$33.7B
86
INSMInsmed, Inc.$27.0B
84
ROIVRoivant Sciences Ltd.$25.9B
36
MRNAModerna, Inc.$25.3B
75
INCYIncyte Corp.$24.0B
90
RVMDRevolution Medicines, Inc.$42.5B
35

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Alnylam Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALNY news & analysis

Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm

PRNewsWire · 16 Aug 2026negative

Kessler Topaz Meltzer & Check, LLP announced it is investigating potential violations of federal securities laws by Alnylam Pharmaceuticals on behalf of investors who purchased Alnylam securities and experienced significant financial losses.

Why it matters — A securities law firm has opened an investigation into Alnylam, which could signal regulatory or legal scrutiny relevant to investors who suffered losses in the company's stock.

Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing

The Motley Fool · 16 Aug 2026positive

Alnylam's stock has plunged following a revenue guidance cut and other concerns, though the full picture for the biotech innovator is reportedly more positive than the sell-off suggests.

Why it matters — An Alnylam watcher would care because the article argues the market may be overlooking more positive aspects of the company's story amid the recent decline.

Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm

GlobeNewsWire · 15 Aug 2026negative

Kessler Topaz Meltzer & Check, LLP is investigating potential federal securities law violations by Alnylam Pharmaceuticals and is encouraging investors who suffered significant financial losses to contact the firm.

Why it matters — A securities law investigation and investor solicitation by a litigation firm could signal potential legal or disclosure issues for Alnylam that may affect shareholder value.

NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm

Business Wire · 14 Aug 2026negative

Kessler Topaz Meltzer & Check, LLP announced it is investigating potential violations of federal securities laws by Alnylam Pharmaceuticals on behalf of investors who experienced significant losses. The investigation follows Alnylam's disappointing second-quarter financial results reported on July 30, 2026.

Why it matters — ALNY watchers would care because the firm now faces a securities-law investigation tied to disappointing financial results, adding legal and reputational uncertainty.

Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Continuing Securities Fraud Investigation

GlobeNewsWire · 13 Aug 2026negative

Law Offices of Howard G. Smith announced it is continuing its investigation into Alnylam Pharmaceuticals, Inc. on behalf of investors, concerning the company's possible violations of federal securities laws. The announcement was made on Aug. 13, 2026.

Why it matters — An ongoing securities-fraud investigation could point to potential legal or disclosure concerns for Alnylam that ALNY shareholders may want to monitor.

FAQ

Frequently asked questions about ALNY stock

What is the ALNY stock price forecast for 2026-2027?

The 27 Wall Street analysts covering Alnylam Pharmaceuticals, Inc. have a median 12-month price target of $354, with estimates ranging from $230 to $536. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALNY stock a buy right now?

Of the 27 analysts covering Alnylam Pharmaceuticals, Inc., 21 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alnylam Pharmaceuticals, Inc. 54 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALNY?

As at 15 Aug 2026, Alnylam Pharmaceuticals, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (97 of 100).

Will ALNY stock go up?

No one can know that. What the data says: the median 12-month target from 27 analysts implies +54.6% from the last close, and Ticker Nerd's factor model ranks Alnylam Pharmaceuticals, Inc. 54 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALNY stock forecast for 2030?

No analyst covering Alnylam Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALNY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $230 to $536 over the next 12 months.

How has ALNY stock performed over the past year?

Alnylam Pharmaceuticals, Inc. returned -48.4% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Alnylam Pharmaceuticals, Inc. do?

Alnylam Pharmaceuticals Inc is a global biopharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of therapeutics based on RNA interference technology. The company focuses on treating genetically defined and other hard-to-treat diseases by silencing specific genes implicated in disease pathways.

What is the latest news on ALNY?

The most recent item we track (PRNewsWire, 16 Aug 2026): "Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm". Kessler Topaz Meltzer & Check, LLP announced it is investigating potential violations of federal securities laws by Alnylam Pharmaceuticals on behalf of investors who purchased Alnylam securities and experienced significant financial losses.

Company

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals Inc is a global biopharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of therapeutics based on RNA interference technology. The company focuses on treating genetically defined and other hard-to-treat diseases by silencing specific genes implicated in disease pathways. Its commercial portfolio includes approved RNAi medicines for rare conditions such as hereditary transthyretin-mediated amyloidosis and primary hyperoxaluria type 1, alongside therapies targeting acute hepatic porphyria and other metabolic and cardiovascular disorders. Alnylam also maintains a broad clinical pipeline in cardiometabolic disease, neuroscience, and hematology, aiming to address areas of high unmet medical need with targeted RNAi-based approaches. The company works across the United States, Europe, and other international markets, supported by strategic collaborations with healthcare providers, commercial partners, and technology firms. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals today plays a central role in bringing RNAi therapeutics into routine medical practice and is widely regarded as a pioneer in this modality.

CEO Dr. Yvonne L. Greenstreet M.B.A., M.D. · 2,500 employees · United States · https://www.alnylam.com